Display Settings:

Format

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Antimicrob Agents Chemother. 2008 Mar;52(3):1179-81. Epub 2007 Dec 17.

Systemic pharmacokinetics of rifaximin in volunteers with shigellosis.

Author information

  • 1Center for Immunization Research, Department of International Health, The Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA. david.taylor@vaxinnate.com

Abstract

Rifaximin is an oral antibiotic indicated for treatment of traveler's diarrhea. Rifaximin pharmacokinetics were evaluated in individuals challenged with Shigella flexneri. Peak plasma rifaximin concentrations were low after nine consecutive doses, and no accumulation was observed. Rifaximin serum levels were minimal and similar to those previously reported in studies of healthy volunteers.

PMID:
18086855
[PubMed - indexed for MEDLINE]
PMCID:
PMC2258548
Free PMC Article

Images from this publication.See all images (1)Free text

FIG. 1.
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire Icon for PubMed Central
    Loading ...
    Write to the Help Desk